Authors: | Iyer, G.; Al-Ahmadie, H.; Schultz, N.; Hanrahan, A. J.; Ostrovnaya, I.; Balar, A. V.; Kim, P. H.; Lin, O.; Weinhold, N.; Sander, C.; Zabor, E. C.; Janakiraman, M.; Garcia-Grossman, I. R.; Heguy, A.; Viale, A.; Bochner, B. H.; Reuter, V. E.; Bajorin, D. F.; Milowsky, M. I.; Taylor, B. S.; Solit, D. B. |
Article Title: | Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer |
Abstract: | We sought to define the prevalence and co-occurrence of actionable genomic alterations in patients with high-grade bladder cancer to serve as a platform for therapeutic drug discovery. An integrative analysis of 97 high-grade bladder tumors was conducted to identify actionable drug targets, which are defined as genomic alterations that have been clinically validated in another cancer type (eg, BRAF mutation) or alterations for which a selective inhibitor of the target or pathway is under clinical investigation. DNA copy number alterations (CNAs) were defined by using array comparative genomic hybridization. Mutation profiling was performed by using both mass spectroscopy-based genotyping and Sanger sequencing. Sixty-one percent of tumors harbored potentially actionable genomic alterations. A core pathway analysis of the integrated data set revealed a nonoverlapping pattern of mutations in the RTK-RAS-RAF and phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathways and regulators of G1-S cell cycle progression. Unsupervised clustering of CNAs defined two distinct classes of bladder tumors that differed in the degree of their CNA burden. Integration of mutation and copy number analyses revealed that mutations in TP53 and RB1 were significantly more common in tumors with a high CNA burden (P < .001 and P < .003, respectively). High-grade bladder cancer possesses substantial genomic heterogeneity. The majority of tumors harbor potentially tractable genomic alterations that may predict for response to target-selective agents. Given the genomic diversity of bladder cancers, optimal development of target-specific agents will require pretreatment genomic characterization. |
Keywords: | adult; aged; aged, 80 and over; middle aged; genetics; mutation; cancer staging; neoplasm staging; proto oncogene; gene amplification; phosphatidylinositol 3 kinase; bladder tumor; urinary bladder neoplasms; tumor suppressor gene; genes, erbb-2; genes, p53; dna copy number variations; copy number variation; transcription factor e2f3; phosphatidylinositol 3-kinases; e2f3 transcription factor; very elderly; e2f3 protein, human; pik3ca protein, human |
Journal Title: | Journal of Clinical Oncology |
Volume: | 31 |
Issue: | 25 |
ISSN: | 0732-183X |
Publisher: | American Society of Clinical Oncology |
Date Published: | 2013-09-01 |
Start Page: | 3133 |
End Page: | 3140 |
Language: | English |
DOI: | 10.1200/jco.2012.46.5740 |
PUBMED: | 23897969 |
PROVIDER: | scopus |
PMCID: | PMC3753703 |
DOI/URL: | |
Notes: | --- - "Export Date: 2 December 2013" - "Source: Scopus" |